Cyxone to propose new share issue to complete Rabeximod acquisition
As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.Cyxone plans to conduct a new, so-called Phase 2B trial with Rabeximod under essentially identical conditions, but with the key difference that patients will be treated for twice as long (24 weeks) as the previous Phase 2 trial. Taking Rabeximod through a complete Phase